Skip to main content
. 2024 Feb 26;16(5):938. doi: 10.3390/cancers16050938

Figure 2.

Figure 2

Homologous recombination deficiency sensitizes to PARP inhibition. Homologous recombination (HR) deficiency can result from loss of HR genes such as BRCA1 and BRCA2, which creates synthetic lethality with PARP inhibition. This may be a strategy that can be implemented to treat LMS with HR deficiency. Created with BioRender.com (accessed on 2 February 2024).